Ancer™ - The "Answer" to Cancer
Superior Neo-Epitope Selection Powered by
Advanced In-Silico Machine-Learning Algorithms
Traditional Neo-Epitope selection methods are cumbersome, non-validated and generate Neo-Epitopes that are mostly non-immunogenic or that can potentially trigger an immune suppressive response.
EpiVax Oncology's Ancer™ neoantigen prediction platform, leverages EpiVax's EpiMatrix® and JanusMatrix™ algorithms, state-of-the-art tools that have been externally validated in several prospective vaccine studies and that are broadly utilized worldwide by pharmaceutical and biotechnology companies. The Ancer™ in silico platform is powered by machine learning based algorithms that prioritize both CD8 and CD4 T cell neoepitopes. Ancer™ enables the rapid, in silico, discovery and removal of inhibitory "Self-Like" Treg neoepitopes, whose activation may curtail efficacy of current TAA based cancer immunotherapies. Ancer™ is designed to enable the discovery of highly immunogenic neoantigens for precision cancer immunotherapies.
Ancer™ is differentiated from other Neo-Epitope prediction tools (the other tools are based on the publicly available IEDB and NET-MHC based algorithms which we have shown to be inaccurate). Note that most approaches combine mass spectrometry or elution methods to increase the accuracy of their predictive algorithms. These additional steps are cumbersome and labor intensive. Ancer™ does not require any other epitope selection methods, it is 100% in silico.
Ancer™ to Cancer. The Ancer™ cancer Neo-Epitope selection platform integrates EpiVax’s in silico, predictive algorithms which have already been validated such as EpiMatrix™ and JanusMatrix™ built and continuously improved over the last 20 years.
EpiMatrix®. Ancer™ (EpiMatrix) prioritizes both Class I (CD8) AND Class II (CD4) highly immunogenic T cell Neo-Epitopes that are recognized as “Non-Self” to generate an effective T cell response.
JanusMatrix™. Ancer™ (JanusMatrix) selects out "Self-Like" epitopes that can lead to both immune suppression (Treg) and immune-related adverse events.
End-to-End. Ancer™ is integrated into an end-to-end, GMP ready, robust and already established commercial-grade platform.
Finally, and importantly, we have performed head to head comparisons and we have showed, consistently, a significantly higher epitope prediction accuracy. Thus, leading to potentially more potent and safer therapeutic cancer vaccines.